PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech Income Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 31, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020
Selling, General & Admin	4.1	6.11	5.99	3.7	2.71	3.53
Research & Development	0.41	0.41	0.47	0.69	0.92	0.3
Operating Expenses	4.5	6.52	6.46	4.39	3.62	3.83
Operating Income	-4.5	-6.52	-6.46	-4.39	-3.62	-3.83
Interest Expense	-	-	-	-0	-0	-0
Interest & Investment Income	1.93	3.4	1.94	0.16	-	-
Other Non Operating Income (Expenses)	13.12	5.45	0.2	-0	-0	-0
EBT Excluding Unusual Items	10.55	2.33	-4.32	-4.24	-3.63	-3.83
Asset Writedown	-2	-2	-	-	-	-
Other Unusual Items	-	-	-	-	0.08	-
Pretax Income	20.25	0.33	-4.32	-4.24	-3.55	-3.83
Net Income	20.25	0.33	-4.32	-4.24	-3.55	-3.83
Preferred Dividends & Other Adjustments	10.28	17.57	-	-	-	-
Net Income to Common	9.98	-17.24	-4.32	-4.24	-3.55	-3.83
Shares Outstanding (Basic)	8	10	19	16	1	1
Shares Outstanding (Diluted)	8	10	19	16	1	1
Shares Change (YoY)	-35.50%	-50.84%	25.56%	971.73%	60.24%	23.23%
EPS (Basic)	1.29	-1.80	-0.22	-0.27	-2.45	-4.23
EPS (Diluted)	1.29	-1.80	-0.22	-0.27	-2.45	-4.23
EBIT	-4.5	-6.52	-6.46	-4.39	-3.62	-3.83

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q